Slovakia

The earlier partial version of this page recorded Slovakia as a pharmacist-only ownership market. That was an error carried from a secondary summary, and it inverted the conclusion.

§3 ods. 5 of zákon č. 362/2011 Z.z. on medicines and medical devices provides that a permit to operate a pharmacy may be issued to a natural person or a právnická osoba. Where the holder is a legal entity, or a natural person without the professional qualification, it must appoint an odborný zástupca, a pharmacist who is professionally responsible for the pharmacy’s operation. The permit is issued by the regional self-governing authority, the samosprávny kraj.

The market confirms the reading. Dr.Max Holding SK operates the largest network, and BENU, part of the Phoenix group, runs a second chain. Neither is pharmacist-owned in any meaningful sense.

For a founder, Slovakia therefore belongs in the same ownership bracket as Czechia, Poland and Hungary rather than with Germany or Austria.

Slovakia is one of the few smaller markets where the manufacturer’s own self-pay list prices are published rather than inferred from pharmacy shelves. Novo Nordisk set official Slovak Wegovy prices effective 1 February 2026:

• 145.21 euros per pen at the lower maintenance strengths
• 170.84 euros per pen at the middle strengths
• 196.61 euros per pen at the top strength

Those are list prices at the point of supply, before any pharmacy margin or dispensing fee, so patient-facing prices sit above them. The pattern matters more than the exact numbers: a manufacturer publishing a tiered self-pay price schedule in a five-million-person market is treating cash-pay obesity as a real channel, not an overflow from diabetes.

Obesity carries no reimbursement. Semaglutide as Ozempic is reimbursed only for type 2 diabetes, subject to the standard indication limits and specialist prescribing, which mirrors the Czech arrangement. Wegovy, Saxenda and Mounjaro for weight management are paid in full by the patient.

That means the addressable market is defined by disposable income rather than by an insurer’s criteria, and the operator’s competition is other cash channels, including cross-border purchasing into Austria and Czechia and grey-market supply.

Zásielkový výdej, mail-order dispensing, is regulated under zákon 362/2011 and, as in Czechia, is confined to medicines whose authorisation does not restrict them to prescription. A GLP-1 cannot be shipped to a Slovak patient by a Slovak pharmacy.

The workable shape is therefore identical to the Czech one: own or partner with a physical pharmacy, run the consultation and prescription digitally through eZdravie, and complete the transaction at the counter. The convenience gain is in the prescribing and adherence layer, not the logistics.